‘Decentralized Clinical Trials 2.0’ On The Horizon
Executive Summary
The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, the Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead.
You may also be interested in...
Decentralized Clinical Trials ‘No Longer A Leap Of Faith’
This second segment of a two-part Pink Sheet article on decentralized clinical trials looks at ensuring that staff at study sites are on onboard to support fast-paced change in this field, how regulatory guidance can help tackle hesitancy, and the need to transparently track such studies.
EU Aims To Drive Uptake In Decentralized Clinical Trials With Harmonized Guide
The highly anticipated pan-EU recommendation paper on decentralized clinical trials explains the factors that sponsors should consider when designing and implementing such trials.
How Should The US Government Coordinate Emergency Clinical Trials?
Research institutions, CROs, biopharma industry and other stakeholders are asked to comment on potential governance structure that would determine when trials are needed to address disease outbreaks and other public health emergencies.